One study found that tirzepatide improved several key markers of heart health in patients with obesity: Reduced inflammation markers associated with heart damage Improved insulin sensitivity, which benefits heart metabolism Decreased fat deposits around the heart (epicardial fat) Supported healthy blood pressure changes without causing dangerous drops The STEP-HFpEF trial specifically examined semaglutide (a similar GLP-1 medication) in heart failure patients with preserved ejection fraction (HFpEF) and found that participants taking the medication showed: Improved exercise capacity measured by the 6-minute walk test Better quality of life scores on heart failure questionnaires Reduced hospitalisations for heart failure compared to placebo Significant weight loss averaging 13.3% of body weight after 52 weeks The STEP-HFpEF findings, along with early results from the ongoing SUMMIT study examining tirzepatide in heart failure, suggest that GLP-1 receptor agonists may be particularly beneficial for heart failure patients
You might experience a temporary uptick in nausea or digestive issues for several days after moving to a higher dose, even if you were feeling fine on your previous dose
Any provider offering it without a medical evaluation is unsafe and illegitimate
During your visit, well assess whether Semaglutide is right for you, explain how the process works, and develop a realistic timeline for your goals
The main goals are steady metabolism, stable appetite, and ongoing support, not fast weight loss
